

APPENDIX I

TABLE OF CONTENTS

I.	REAL PARTY IN INTEREST	2
II.	NO RELATED APPEALS OR INTERFERENCES	2
III.	STATUS OF CLAIMS	2
IV.	STATUS OF AMENDMENTS	2
V.	SUMMARY OF INVENTION	2
VI.	ISSUES	4
VII.	GROUPING OF CLAIMS	4
VIII.	ARGUMENT	6
	A. The Prosecution History and Evidence of Record	6
	1. The Claims Involved in the Appeal	6
	2. The Rejection Arguments	7
	3. The Responsive Arguments of Record	9
	4. The Supplemental Declaration of Vernon E. Scholes, Ph.D.	11
	Expert Qualifications and Experience	12
	Scope of Review	12
	“Normal” Means Normal-Functioning Lymphocytes	13
	No Separation of “Normal” Lymphocytes Prior to Propagation Is Required	14
	Youdim et al. Does Not Disclose or Suggest Propagating Cells or Autologous Factor (ALF)	14
	Warren Does Not Disclose or Suggest Propagating Cells or Autologous Factor (ALF)	14
	Invention Not Obvious Based on Hypothetical Combination of Youdim et al. and Warren	15
	5. The Advisory Action After Final	16
	6. Impasse and Issues on Appeal	16
	B. Claims 49-66 Are Not Obvious Over Youdim et al. in view of Warren ..	17
	C. Claims 52-54, 60-64, and 66 Are Separately Patentable and Not Obvious ..	19
	D. Claims 65-66 Are Supported by the Originally-Filed Specification	20
	E. Claims 65-66 Do Not Include “Indefinite” Language	21
IX.	REFERENCE TO APPENDIX	21
X.	CONCLUSION	22

APPENDIX A - Copy of the claims involved in the appeal.

APPENDIX B - Youdim, Rea, and Liang, "Treatment of Environmentally Sensitive Patients with Transfer Factor Part I: Immunologic Studies," *Clinical Ecology*, vol. 7, pp. 55-61, 1990.

APPENDIX C - Warren et al., U.S. Patent No. 4,435, 384 issued March 6, 1984.

APPENDIX D - Supplemental Declaration of Vernon E. Scholes, Ph.D.